Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate in psoriatic polyarthritis

P D Pigatto1, E Gibelli, R Ranza

  • 1Department of Dermatology, University of Milan, Italy.

Acta Dermato-Venereologica. Supplementum
|January 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The International Guideline for the Definition, Classification, Diagnosis and Management of Urticaria.

Allergy·2026
Same author

Parosteal osteosarcoma of the thumb: A case report and literature review.

Hand surgery & rehabilitation·2022
Same author

Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020
Same author

International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings.

Clinical rheumatology·2020
Same author

Outbreak of Bacterial Blossom Blight Caused by Pseudomonas viridiflava on Actinidia chinensis Kiwifruit Plants in Italy.

Plant disease·2019
Same author

Predictors of response to omalizumab and relapse in chronic spontaneous urticaria: a study of 470 patients.

Journal of the European Academy of Dermatology and Venereology : JEADV·2018

Methotrexate (MTX) effectively treats psoriatic polyarthritis, reducing joint swelling, pain, and psoriasis severity. Most patients benefit, with maximum efficacy observed within six months of treatment.

Area of Science:

  • Rheumatology
  • Dermatology
  • Pharmacology

Background:

  • Methotrexate (MTX) is a recognized treatment for psoriasis and chronic polyarthritis.
  • Psoriatic polyarthritis involves both skin and joint inflammation.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Methotrexate (MTX) in patients with psoriatic polyarthritis.
  • To determine the optimal treatment duration for MTX in this patient population.

Main Methods:

  • Retrospective analysis of 54 psoriatic polyarthritis patients treated with MTX.
  • Data collected included patient demographics, disease duration, MTX dosage (10-12.5 mg/week), and treatment outcomes.
  • Assessment of efficacy using joint counts, disease activity scores, ESR, CRP, and Psoriasis Activity and Severity Index (PASI).

Related Experiment Videos

Main Results:

  • Significant reductions were observed in swollen/tender joint counts, global disease activity, ESR, and CRP.
  • Psoriasis severity, assessed by PASI, also showed significant improvement.
  • 40% of patients reduced their intake of symptomatic drugs.
  • 60% of patients continued MTX treatment, with 32 still on therapy after a mean of 1.6 years.

Conclusions:

  • Methotrexate (MTX) is a valuable treatment for a majority of psoriatic polyarthritis patients.
  • The drug demonstrates significant efficacy in improving both articular and cutaneous manifestations.
  • Maximum therapeutic benefit from MTX is typically achieved within six months of initiating therapy.